-+ 0.00%
-+ 0.00%
-+ 0.00%

IFINATAMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR CERTAIN PATIENTS WITH PREVIOUSLY TREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

Reuters·09/25/2026 20:31:05